Four OICR-funded studies are exploring transformative approaches in cancer care, leveraging existing research and patient contributions to advance cancer detection, diagnosis, and treatment. These studies, collectively known as the CATALYST program, are designed to maximize the impact of available data and samples, pushing the boundaries of clinical practice.
One study led by Dr. Neil Fleshner aims to investigate the potential of a common diabetes medication, metformin, in preventing blood cancers. Building on previous research showing metformin's ability to impede the growth of cells with a specific genetic mutation, this study will further explore its effectiveness through genetic testing. This approach not only showcases the power of reanalyzing existing data but also highlights the potential for personalized medicine in cancer treatment.
Another CATALYST project, led by Dr. Hon Leong and Dr. Lillian Siu, focuses on developing a blood test to predict treatment response to immunotherapy. By analyzing the presence of 'endogenous retrotransposable elements' (ERE) in blood samples, they aim to identify patients who will benefit most from this innovative treatment. This study emphasizes the importance of patient-centric research, ensuring that their contributions are directly translated into improved care.
Dr. Enrique Sanz Garcia and Dr. Scott Bratman are working on a blood test to predict the recurrence of head and neck cancer. By applying advanced genomic sequencing technology to detect tiny fragments of tumour DNA in blood samples, they hope to identify patients at high risk of cancer recurrence. This study not only showcases the potential of liquid biopsy but also underscores the importance of early detection in cancer management.
Lastly, Dr. Vikas Gupta and Dr. James Kennedy are developing a system to predict treatment response in patients with rare blood cancer, myelofibrosis. By reanalyzing existing data and risk scoring tools, they aim to identify suitable patients for bone marrow transplant and determine the optimal timing for this potentially life-saving treatment. This study highlights the value of data reanalysis in cancer research, allowing for more informed decision-making and personalized treatment strategies.
These CATALYST studies are a testament to the power of collaboration between researchers, patients, and funding organizations. By leveraging existing data and samples, these projects are not only advancing our understanding of cancer but also improving patient outcomes. As Dr. David Cescon, Scientific Director of OICR's Clinical Translation research theme, emphasizes, these studies honor the patients' contributions and maximize the impact of research, ultimately leading to better lives for those affected by cancer.
The CATALYST program is a prime example of how innovative funding streams can drive progress in cancer research. By supporting these studies, the Ontario Institute for Cancer Research (OICR) is not only advancing scientific knowledge but also ensuring that patient contributions are valued and translated into tangible benefits. As Nolan Quinn, Minister of Colleges, Universities, Research Excellence and Security, aptly states, staying ahead of cancer requires a proactive approach, and the CATALYST program is a significant step in that direction.
